Table 1.
Chi-square test results of the correlation between the clinical pathological factors and recurrence of cholangiocarcinoma after radical surgery.
| Variable | No-recurrence group [cases(%)] | Recurrence group [cases(%)] | P value |
|---|---|---|---|
| Sex | |||
| Female | 17 (33.3) | 55 (35.3) | 0.80 |
| Male | 34 (66.7) | 101 (64.7) | |
| Age (years) | |||
| <60 | 30 (58.8) | 84 (53.8) | 0.54 |
| ≥60 | 21 (41.2) | 72 (46.2) | |
| WBC (10^9/L) | |||
| <10 | 45 (88.2) | 138 (88.5) | 0.97 |
| ≥10 | 6 (11.8) | 18 (11.5) | |
| HB (g/L) | |||
| <120 | 16 (31.4) | 50 (32.1) | 0.93 |
| ≥120 | 35 (68.6) | 106 (67.9) | |
| ALB (g/L) | |||
| <35 | 13 (25.5) | 42 (26.9) | 0.84 |
| ≥35 | 38 (74.5) | 114 (73.1) | |
| AFP (ug/L) | |||
| <10 | 50 (98.0) | 149 (95.5) | 0.42 |
| ≥10 | 1 (2.0) | 7 (4.5) | |
| CEA (ug/L) | |||
| <5 | 43 (84.3) | 132 (84.6) | 0.96 |
| ≥5 | 8 (15.7) | 24 (15.4) | |
| CA19-9 (U/ml) | |||
| <35 | 20 (39.2) | 38 (24.4) | 0.04 |
| ≥35 | 31 (60.8) | 118 (75.6) | |
| Tumor number | |||
| Single | 48 (94.1) | 147 (94.2) | 0.98 |
| Multiple | 3 (5.9) | 9 (5.8) | |
| Tumor size(cm) | |||
| <5 | 44 (86.3) | 128 (82.1) | 0.49 |
| ≥5 | 7 (13.7) | 28 (17.9) | |
| Vascular invasion | |||
| No | 48 (94.1) | 128 (82.1) | 0.04 |
| Yes | 3 (5.9) | 28 (17.9) | |
| Pathological type | |||
| Intrahepatic | 10 (19.6) | 33 (21.1) | 0.87 |
| Perihilar | 5 (29.4) | 50 (32.1) | |
| Distal | 26 (51.0) | 73 (46.8) | |
| Differentiation degree | |||
| Poor | 15 (29.4) | 63 (40.4) | 0.37 |
| Moderate | 31 (60.8) | 81 (51.9) | |
| Well | 5 (9.8) | 12 (7.7) | |
| TNM stage | |||
| I | 18 (35.3) | 37 (23.7) | 0.22 |
| II | 22 (43.1) | 86 (55.1) | |
| III | 11 (21.6) | 33 (21.2) | |
| Adjuvant chemotherapy | |||
| Single drug | 1 (5) | 14 (32.6) | 0.02 |
| Doublet drugs | 19 (95) | 29 (67.4) |
WBC, white blood cell; HB, hemoglobin; ALB, albumin; AFP, alpha fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; Single drug, mainly 5-fluorouracil (S-1 or capecitabine) adjuvant chemotherapy was administrated as follow:S-1 50 mg/m2 or capecitabine 1250 mg/m2 administered orally twice daily on days 1–14 for a 3-week cycle; Doublet drugs, mainly gemcitabine + capecitabine or S-1 adjuvant chemotherapy was administrated as follow: gemcitabine 1000 mg/m2 administered intravenously on day 1 and S-1 50 mg/m2 or capecitabine 1000 mg/m2 administered orally twice daily on days 1–14 for a 3-week cycle.